Aimmune Therapeutics Inc logo

AIMT - Aimmune Therapeutics Inc News Story

$34.49 0.0  0.0%

Last Trade - 12/10/20

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £412k
Position in Universe th / 6858

Aimmune shareholders accept $2 billion Nestle tender offer

Tue 13th October, 2020 6:37am
ZURICH, Oct 13 (Reuters) - Aimmune Therapeutics Inc  AIMT.O 
shareholders have backed Nestle's  NESN.S  $2 billion offer to
gain full ownership of the first U.S.-approved peanut allergy
treatment, which has struggled with a slow launch due to the
COVID-19 pandemic.
    Including shares it already held, Nestle controlled around
84% of the outstanding shares as of the $34.50 per share offer's
expiration date. "The minimum tender condition to the
consummation of the offer set forth in the offer to purchase has
been satisfied," Nestle said.  urn:newsml:reuters.com:*:nL8N2FX0IV
    

 (Reporting by Michael Shields, editing by Kirsti Knolle)
 ((Michael.Shields@thomsonreuters.com; +41 41 528 3630; Reuters
Messaging: michael.shields.thomsonreuters.com@reuters.net))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.